ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ELOX Eloxx Pharmaceuticals Inc

3.82
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Eloxx Pharmaceuticals Inc ELOX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 3.82 10:00:00
Open Price Low Price High Price Close Price Previous Close
3.82 3.82
more quote information »

Recent News

Date Time Source Heading
16/4/202421:30GLOBEEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program..
02/4/202407:02EDGAR2Form NT 10-K - Notification of inability to timely file Form..
30/3/202407:11EDGAR2Form 8-K - Current report
22/3/202405:20EDGAR2Form 25-NSE - Notification filed by national security..
15/3/202407:30EDGAR2Form 8-K - Current report
14/3/202402:42GLOBEAlmirall and Eloxx Pharmaceuticals Enter into Exclusive..
27/1/202408:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202408:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/1/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202413:44EDGAR2Form S-3 - Registration statement under Securities Act of..
25/1/202409:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/1/202409:10EDGAR2Form 8-K - Current report
29/12/202308:11EDGAR2Form 8-K - Current report
14/11/202308:15GLOBEEloxx Pharmaceuticals Reports Third Quarter 2023 Financial..
17/10/202308:26EDGAR2Form 8-K - Current report
09/10/202323:00GLOBEEloxx Pharmaceuticals Reports Additional Confirmation that..
21/9/202306:05EDGAR2Form 8-K - Current report
21/9/202303:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/9/202322:00GLOBEEloxx Pharmaceuticals Announces $2 Million Registered Direct..
18/9/202322:05EDGAR2Form 8-K - Current report
18/9/202321:00GLOBEEloxx Pharmaceuticals Reports Independent Confirmation of..
16/9/202307:15EDGAR2Form 8-K - Current report
08/9/202300:14EDGAR2Form 8-K - Current report
07/9/202323:00GLOBEEloxx Pharmaceuticals Provides Program Updates on ELX-02 and..
30/8/202306:32EDGAR2Form 8-K - Current report
22/8/202306:50EDGAR2Form 8-K - Current report
15/8/202301:56EDGAR2Form 8-K - Current report
14/8/202322:30GLOBEEloxx Pharmaceuticals Reports Second Quarter 2023 Financial..
14/8/202322:00GLOBEEloxx Pharmaceuticals Reports Drug Response in All Patients..
12/8/202306:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/8/202306:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202306:01EDGAR2Form 8-K - Current report
03/8/202323:26GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
13/7/202322:43EDGAR2Form 8-K - Current report
10/7/202323:00GLOBEEloxx Pharmaceuticals Announces Publication Demonstrating..
28/6/202323:00GLOBEEloxx Pharmaceuticals Key Opinion Leader Event Highlights..
22/6/202303:30GLOBEEloxx Pharmaceuticals to Host Investor and Analyst Call on..
21/6/202323:00GLOBEEloxx Pharmaceuticals Highlights Recent Alport Syndrome..
15/6/202306:53GLOBEEloxx Pharmaceuticals Announces Final Data Assessment from..
06/6/202322:30GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
01/6/202323:10GLOBEAtossa Appoints Life Sciences Financial and Operations..
24/5/202322:00GLOBEEloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal..
16/5/202306:30GLOBEEloxx Pharmaceuticals Reports First Quarter 2023 Financial..
02/5/202322:00GLOBEEloxx Pharmaceuticals Announces FDA Clearance to Begin..

Your Recent History

Delayed Upgrade Clock